Helius Medical's Equity Plan Growth Signals Potential Executive Compensation Changes
Rhea-AI Filing Summary
Helius Medical Technologies (NASDAQ: HSDT) has reported a significant amendment to its 2022 Equity Incentive Plan following stockholder approval at a special meeting held on May 23, 2025. The amendment, initially adopted by the Board on April 22, 2025, has resulted in a substantial increase in the company's equity compensation pool.
Key developments:
- The Plan's share pool increased to 7.1 million shares on June 16, 2025
- The increase represents 20% of Fully Diluted Shares following the company's first registered offering after May 15, 2025
- The amendment was triggered by the completion of a Public Offering
This expansion of the equity incentive plan suggests Helius Medical Technologies is strengthening its ability to attract and retain talent through equity-based compensation. The significant increase in available shares indicates the company's commitment to aligning employee interests with shareholder value.
Positive
- None.
Negative
- Significant dilution risk as the company increased its equity incentive plan share pool to 7.1 million shares, representing a 20% increase in fully diluted shares
Insights
Helius Medical increased equity incentive plan shares to 7.1 million, potentially diluting existing shareholders while enhancing employee compensation capacity.
Helius Medical Technologies has significantly expanded its 2022 Equity Incentive Plan, increasing the available share pool to 7.1 million shares as of June 16, 2025. This expansion, representing 20% of fully diluted shares, was approved by stockholders on May 23, following the Board's recommendation and a subsequent public offering. The substantial increase in available equity gives the company considerably more flexibility for employee compensation, retention, and recruitment - critical factors for medical technology companies competing for specialized talent.
From a compensation perspective, this move likely signals preparation for either broader distribution of equity across the organization or more significant grants to key executives and employees. While beneficial for talent management, the expansion creates meaningful dilution potential for existing shareholders. The timing following a public offering suggests management is using the improved liquidity position to strengthen its compensation framework. The magnitude of the increase (resulting in 7.1 million shares available) appears substantial relative to the company's size, indicating this is a significant enhancement to their compensation capabilities rather than a routine adjustment.
8-K Event Classification
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 22, 2025, the Company’s Board of Directors (the “Board”), upon the recommendation of the Compensation Committee of the Board, adopted an amendment to the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan (the “Plan”), subject to stockholder approval, pursuant to which the aggregate number of shares of common stock that may be issued pursuant to the Plan will be increased by an amount equal to 20% of the Fully Diluted Shares (as defined in the Plan) on the 10th calendar date following the first closing of a registered offering of the Company’s common stock that occurs on or after May 15, 2025 (the “Equity Plan Amendment”). Our stockholders approved the Equity Plan Amendment at the special stockholders meeting held on May 23, 2025. On June 16, 2025, the 10th calendar day following the closing of the Public Offering, the aggregate number of shares of common stock available to be issued pursuant to the Plan increased to 7.1 million shares.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HELIUS MEDICAL TECHNOLOGIES, INC. | ||
|
|
|
|
Dated: June 20, 2025 |
| By: | /s/ Jeffrey S. Mathiesen |
|
|
| Jeffrey S. Mathiesen |
|
|
| Chief Financial Officer, Treasurer and Secretary |
3